News

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...
Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...
India's Tata Communications reported a 15% rise in its fourth-quarter profit on Tuesday, helped by higher demand for its data services.
Regeneron Pharmaceuticals saw its share price ... A strategic move was the initiation of a quarterly cash dividend at US$0.88 per share and a share repurchase program valued at US$3 billion ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Medical device maker Abbott Laboratories maintained its annual profit forecast on Wednesday and said it expected the U.S.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Evergreen Capital Management boosted its Regeneron stake by 362.9%, snatching up 3,030 more shares and flexing some serious ...
Capital Group Private Client Services Inc. reduced its Regeneron holdings by 17.6% in Q4, offloading 19,565 shares, but still ...